Doctor Baravan Al-Kassou

Doctor Baravan Al-Kassou

University hospital Bonn, Bonn (Germany)

Member of:

Dr. Al-Kassou is an interventional cardiologist and a clinical researcher at the Heart Center of the University Hospital Bonn in Germany. His research focuses on structural heart interventions, specifically in patients with severe aortic stenosis. Within this field, his work is dedicated to optimizing risk stratification and improving procedural safety. In addition, Dr. Al-Kassou is actively engaged in investigating the complex genetic architecture underlying aortic valve stenosis. He serves as a Project Leader of GUARD (Genes Underlying AoRtic valve Disease), a project funded by the German Research Foundation. Through this initiative, Dr. Al-Kassou leads efforts to elucidate the genetic risk factors associated with the development of aortic stenosis.

Presentations

Cholesterol crystal dissolution rate of serum is associated with iliofemoral calcification and predicts outcomes in patients undergoing TAVR

Event: ESC Congress 2023

Topic: Intervention

Session: Advances and remaining challenges in percutaneous valve intervention

Access

Myocardial infarction with ST-segment elevation caused by caseous mitral annular calcification

Event: ESC Congress 2023

Topic: Clinical

Session: Coronary disorders

Access

Hemodynamic effects and challenges of combined use of extracorporeal membrane oxygenation and ventricular support for refractory cardiogenic shock: a case report

Event: ESC Congress 2023

Topic: Clinical

Session: Acute cardiac care (1)

Access

Safety and efficacy of protamine administration for prevention of bleeding complications in patients with recent PCI undergoing TAVR

Event: ESC Congress 2023

Topic: Intervention

Session: Walking the line between bleeding and thrombosis in valvular heart disease

Access

The association of CT-assessed fat-free muscle fraction with frailty and malnutrition and the predictive value of their combination in patients undergoing TAVR

Event: ESC Congress 2023

Topic: Epidemiology, Prognosis, Outcome

Session: Predictors of outcomes in transcatheter aortic valve implantation

Access

Incidence and management of multiple native valvular heart disease in patients undergoing TAVR: Impact of staged valvular interventions on outcomes

Event: ESC Congress 2023

Topic: Intervention

Session: Predictors of outcomes in transcatheter aortic valve implantation

Access

Optimal protamine-to-heparin dosing ratio for the prevention of bleeding complications in patients undergoing TAVR - a multicentre experience

Event: ESC Congress 2022

Topic: Intervention

Session: Challenges in transcatheter aortic valve intervention

Access

Novel assay for quantifying the cholesterol crystal dissolution capacity of serum predicts outcomes in patients with severe aortic stenosis undergoing TAVR

Event: ESC Congress 2022

Topic: Aortic Valve Stenosis

Session: Pathophysiology and disease progression in aortic stenosis

Access

Impact of frailty status on 30-day mortality in patients with valvular heart disease undergoing percutaneous transcatheter valve interventions

Event: ESC Congress 2019

Topic: Aortic Valve Intervention

Session: Non-coronary cardiac intervention

Access

Prognostic value of logistic EuroSCORE and STS-PROM in a recent patient cohort undergoing TAVI with next generation transcatheter heart valves

Event: ESC Congress 2018

Topic: Intervention

Session: Outcome prediction tools after valve intervention

Access

Doctor Baravan Al-Kassou

Biography

Contributor content

Cholesterol crystal dissolution rate of serum is associated with iliofemoral calcification and predicts outcomes in patients undergoing TAVR

Myocardial infarction with ST-segment elevation caused by caseous mitral annular calcification

Hemodynamic effects and challenges of combined use of extracorporeal membrane oxygenation and ventricular support for refractory cardiogenic shock: a case report

Safety and efficacy of protamine administration for prevention of bleeding complications in patients with recent PCI undergoing TAVR

The association of CT-assessed fat-free muscle fraction with frailty and malnutrition and the predictive value of their combination in patients undergoing TAVR

Incidence and management of multiple native valvular heart disease in patients undergoing TAVR: Impact of staged valvular interventions on outcomes

Optimal protamine-to-heparin dosing ratio for the prevention of bleeding complications in patients undergoing TAVR - a multicentre experience

Novel assay for quantifying the cholesterol crystal dissolution capacity of serum predicts outcomes in patients with severe aortic stenosis undergoing TAVR

Impact of frailty status on 30-day mortality in patients with valvular heart disease undergoing percutaneous transcatheter valve interventions

Prognostic value of logistic EuroSCORE and STS-PROM in a recent patient cohort undergoing TAVI with next generation transcatheter heart valves

ESC 365 is supported by